C Difficile Infection

The prototype is being tested in clinical trials involving live microbiota therapeutics as a treatment for recurrent C difficile infections.

Patients who receive a solid organ transplant and develop CDI are at an increased risk for an acute kidney injury.

These changes to the previous 2013 ACG Guidelines feature evidence-based guidance for the evaluation of gastroesophageal reflux disease that include pharmacologic, lifestyle, surgical, and endoscopic management efforts.

A positive CDI test was more common in patients with suffered an aneurysmal subarachnoid hemorrhage than it was in patients with intracerebral hemorrhage or ischemic stroke.

Higher body mass index was seen as a protective factor for C difficile infections.

The data regarding the safety and efficacy of fecal microbiota transplantation for patients with C difficile infections and inflammatory bowel disease has been limited.

Patients with COVID-19 were not at an increased risk of developing CDI.

Dr. Carl V. Crawford led a panel in discussing treatments in the pipeline for CDI.

At least 3 companies have presented later phase data on live microbiota therapies for treating recurrent C difficile infections in 2021.

Bincy Abraham, MD, led the State of Science program on C difficile infections.

An overview of the risk factors that contribute to the development of Clostridioides difficile infection in various health care settings.

The State of the Science events allows experts to come together to update on recent research for CDI.

Recent studies have indicated more community spread of C difficile infections.

Comprehensive discussion on the identification of Clostridioides difficile infection, the spectrum of disease, and overall epidemiology.

The panel reflects on how disruption of the gut microbiome leads to the proliferation of Clostridioides difficile.

Several companies are testing live microbiota therapies for C difficile infections.

Shared insight on how disruption of the gut microbiome may occur based on antibiotic exposure, environmental factors, and diet.

Opening their discussion on Clostridioides difficile, experts provide an overview on the gut microbiome and colonization resistance.

There has recently been more community spread of C difficile infections.

Fecal microbiota transplantation recipients did gain weight following the procedure.

Between 2011-2018, hospital admissions for CDI has decreased dramatically.

Dr. Feuerstadt presented data about RBX2660 during the recent ACG 2021 meeting.

Approximately 88% of patients treated with SER-109 achieved a sustained clinical response at 8 weeks.

A new study presented at ACG 2021 shows microbiome therapeutic CP101 effective in preventing recurrent CDI by increasing intestinal microbiome diversity.

It can be challenging to find a suitable donor for fecal microbiota transplantation.

RBX2660 is a a standardized, stabilized, investigational microbiota-based live therapeutic being studied for the treatment of C difficile infections.

Many of the measures put in place because of COVID-19 have also helped to reduce the rates of C difficile infections.

Recent studies have shown the majority of potential FMT donors are ultimately rejected.

Recurrent CDI, severe CDI, and the number of stools were linked to lower Cdiff32 scores.

C difficile was found on 45% of shoe soles and 26.2% of private residences.